FibroGen, Inc. is a San Francisco biopharmaceutical company that spent three decades building first-in-class medicines around hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology. Its best-known drug, roxadustat, is an oral treatment for anemia approved in China, Japan and Europe. After selling its China business to AstraZeneca in 2025 and paying down debt, the company rebranded as Kyntra Bio (Nasdaq: KYNB) in January 2026 to concentrate on oncology and rare disease, led by FG-3246, a first-in-class CD46-targeting antibody-drug conjugate for metastatic prostate cancer.
AmMax Bio is a clinical-stage biotechnology company in Redwood City, California, developing first-in-class cancer therapeutics built on a CSF1R-targeting antibody platform. Founded in 2020 by pharmaceutical veteran Larry Hsu, PhD, in partnership with Amgen, the company advances a pipeline that spans a monoclonal antibody for tenosynovial giant cell tumor (TGCT), a therapy for colorectal cancer minimal residual disease (in partnership with MD Anderson), and a lead antibody-drug conjugate, AMB-104, for acute myeloid leukemia. AmMax's strategy is to de-risk development by combining clinically validated antibodies with established linker-payload technology.
Fortitude Biomedicines is a Waltham, Massachusetts biotech that launched in early 2026 with $13M in seed financing to develop next-generation antibody-based therapies for autoimmune diseases and cancer. Its proprietary GLUE-DAC platform bolts molecular glue degraders onto antibody-drug conjugates, aiming to use catalytic targeted protein degradation to widen the therapeutic window of ADCs and overcome the resistance that has dogged the field. Its lead program, FORT-202, is a first-in-class T-cell targeting bispecific antibody for axial spondyloarthritis expected to reach the clinic in the first half of 2027.
TORL BioTherapeutics is a clinical-stage biopharmaceutical company in Culver City, California developing antibody-based cancer therapies, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Built on discoveries from the UCLA laboratory of Dennis Slamon - the scientist behind Herceptin and Ibrance - TORL is advancing a pipeline against novel cancer targets such as Claudin 6, Claudin 18.2, CDH17, and DLK1. Its lead program, TORL-1-23 (ixotatug vedotin), a CLDN6-targeted ADC, is in pivotal trials for platinum-resistant ovarian cancer. The company has raised over $450 million across multiple rounds, including a $96 million Series C in October 2025.